ENTA is up about $1/sh on the week as I’m typing. ABBV’s share-price decline this week can be explained by the broad biotech sell-off as well as heightened fears that PBMs and other third-party payers will pressure Humira pricing in the next few years, perhaps by encouraging adoption of Humira FoBs.
News 
Market Data 
Discover 
AI
